Clinical Trial Update: A Phase 3 Study of Amifampridine Phosphate in Patients With Lambert Eaton Myasthenic Syndrome (LEMS) [Phase 3]

View source ↗

Summary

Phase 3 study of amifampridine phosphate in Lambert-Eaton myasthenic syndrome has been completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lambert-eaton Myasthenic Syndrome

Drugs mentioned

• Amifampridine phosphate (amifampridine phosphate)

Snippet

Sponsor: Catalyst Pharmaceuticals, Inc. | Conditions: Lambert Eaton Myasthenic Syndrome | Phase 3 | Status: COMPLETED | Results posted: 2018-01-04